Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum

Core Insights - Bio-Path Holdings, Inc. is a biotechnology company focused on developing targeted nucleic acid drugs for cancer and obesity using its proprietary DNAbilize technology [1][3] - The company will present a corporate overview at the Life Sciences Virtual Investor Forum on June 12, 2025 [1][2] Company Overview - Bio-Path is developing a pipeline of RNAi nanoparticle drugs that can be administered via intravenous infusion [3] - The lead product candidate, prexigebersen (BP1001), is in a Phase 2 study for blood cancers, while BP1001-A is in a Phase 1/1b study for solid tumors and is also being evaluated for obesity and Type 2 diabetes [3] - The second product, BP1002, targets the Bcl-2 protein and is being evaluated for blood cancers, including acute myeloid leukemia [3] - An IND application for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide, is expected to be filed [3]